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Abstract
Objective—Enzymatic degradation of the extracellular matrix is known to be powerful regulator
of atherosclerosis. However, little is known about the enzymatic regulation of heparan sulfate
proteoglycans (HSPGs) during the formation and progression of atherosclerotic plaques.
Methods and Results—Swine were rendered diabetic through streptozotocin injection and
hyperlipidemic through a high fat diet. Arterial remodeling and local endothelial shear stress
(ESS) were assessed using intravascular ultrasound, coronary angiography and computational
fluid dynamics at weeks 23 and 30. Coronary arteries were harvested and 142 arterial subsegments
were analyzed using histomorphologic staining, immunostaining and real time PCR. Heparanase
staining and activity was increased in arterial segments with low ESS, in lesions with thin cap
fibroatheroma (TCFA) morphology and in lesions with severely degraded internal elastic laminae.
In addition, heparanase staining colocalized with staining for CD45 and MMP-2 within
atherosclerotic plaques. Dual staining with gelatinase zymography and heparanase
immunohistochemical staining demonstrated colocalization of matrix metalloprotease activity with
heparanase staining. A heparanase enzymatic activity assay demonstrated increased activity in
TCFA lesions, subsegments with low ESS and in macrophages treated with oxidized LDL or
angiotensin II.
Conclusions—Taken together, our results support a critical role for heparanase in the
development of vulnerable plaques and suggest a novel therapeutic target for the treatment of
atherosclerosis.
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1. Introduction
During the course of atherosclerotic disease progression, localized plaques develop
throughout the vascular system. While the vast majority of these lesions remain stable, some
undergo changes that make them vulnerable to rupture[1]. This subset of vulnerable plaques
have morphology in which the atherosclerotic remodeling and inflammatory process has
created a thin cap of fibrous tissue over a lipid rich and metabolically active core. These
plaques are prone to acute rupture and are primarily responsible for the development of
acute coronary syndrome and sudden cardiac death[2]. A question of paramount importance
is the specific biological and local vascular factors that cause some atheromas to become
prone to rupture while others remain stable. The past decades of intense research into the
mechanisms of development of vulnerable atheromas has revealed a complex interplay
among multiple aspects of the local vascular environment that ultimately lead to plaque
destabilization. While the essential role of matrix metalloproteases (MMPs) in the
atherosclerotic process is well recognized [3], little is know about the role of enzymatic
regulation of glycosaminoglycans in the formation of atheroma with thin caps.
Proteoglycans are complex molecules consisting of a core protein post-translationally
modified with glycosaminoglycan carbohydrate chains. The proteoglycans were one of the
earliest class of molecules identified to be associated with atherosclerotic lesions and lipid
deposition in the vascular wall [4,5]. Proteoglycans with predominantly chondroitin or
dermatan sulfate chains can retain low density lipoprotein (LDL) and are considered
atherogenic[6]. However the role of heparan sulfate proteoglycans (HSPGs) in atherogenesis
is less clear. Proteoglycans bearing heparan sulfate chains have often been considered anti-
atherogenic[7] due to their ability to inhibit monocyte adhesion[8] and vascular smooth
muscle cell growth[9,10]. However, recent studies in mice with heparan sulfate deficient
perlecan have indicated that heparan sulfate can have pro-atherogenic effects in mouse
models of atherosclerosis as well[11,12].
Heparanase is an endo-β-D-glucuronidase that cleaves a specific motif in heparan sulfate to
create fragments that are 10–20 sugar units long and still biologically active[13]. In this
work, we provide in-vivo evidence that the expression of heparanase is highly regulated in
atherosclerosis and development of vulnerable plaques. Here we demonstrate that
heparanase protein, mRNA and activity are enhanced in regions of low endothelial shear
stress (ESS) and during the progression of atheromas from intermediate lesions to advanced
thin cap fibroatheromas (TCFAs).
2. Methods
2.1. Diabetic, hyperlipidemic swine model of atherosclerosis
All experimental protocols were approved by the Harvard University Animal Care and Use
Committee. Twelve male Yorkshire swine were treated with intravenous infusion of 50 mg/
kg streptozotocin once a day for three days to induce diabetes[14]. The animals were fed a
high fat and cholesterol diet supplemented with sucrose in quantities to maintain total serum
cholesterol between 500–700 mg/dL and blood glucose between 150–350 mg/dL[14].
Twelve animals were assigned to three different treatment groups (n=4 for each group)
including placebo, Valsartan (320 mg per day) or Valsartan in combination with Simvastatin
(40 mg per day). These treatments were added to ensure variation in plaques within the
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segments examined included lesions from all the categories of severity. For analysis the
groups were pooled and analyzed as described below and in the supplemental methods
section. After 23 weeks, the animals underwent vascular profiling using intravascular
ultrasound and coronary angiography for all of the major epicardial coronary arteries as
described previously[15]. At week 30, vascular profiling was repeated and the animals were
euthanized. The mean weight of pigs on the day of euthanasia was 66±4 kg. The mean total
cholesterol during the follow-up period was 611±28 mg/dL, whereas the mean blood
glucose was 230±26 mg/dL. Coronary arteries were harvested, frozen in isopentane cooled
with liquid N2 and stored at −80°C until further analysis. One pig died prior to the second
vascular profiling session and was excluded from the study. Consequently, a total of 31
coronary arteries from 11 pigs were analyzed. The total cholesterol levels among the
treatment groups were placebo (610±41 mg/dL), Simvastatin and Valsartan (564±12 mg/dL)
and Vasartan alone (647±65 mg/dL). The blood glucose levels among the treatment groups
were placebo (246±53 mg/dL), Simvastatin and Valsartan (241±60 mg/dL) and Vasartan
alone (207±42 mg/dL).
The lesions were classified into three categories of plaque progression as proposed by
Virmani et al[1]: minimal (MIN) lesions with minimal lipid deposition and inflammatory
cells; intermediate (INT) lesions with increased lipid accumulation, intima-media ratio of
less than 0.15 and no fibrous cap; and TCFAs with inflamed fibrous cap overlying a necrotic
lipid core. To be considered in the analysis, each subsegment of interest was required to be
free of apparent atherosclerotic plaque at baseline, defined by IVUS as maximum intima–
media thickness (IMT) ≤ 0.5 mm[15]. We defined 4–5 subsegments per artery to contain a
range of segments with low and high endothelial shear stress. Each of these subsegments
was 3 mm in length. Lesions with necrosis but without thin cap morphology were included
in the intermediate category. Lesions were also classified for degradation of the inner elastin
lamina (IEL) based on the following criteria: grade 0, intact IEL; grade 1, few breaks in IEL
(10 or less breaks per field of view); grade 2, many breaks in IEL but with intact intima
media layer (greater than 10 breaks per field of view); grade 3, severely fragmented IEL
with degraded media[15]. Vascular profiling and computational analysis was also used to
determine local ESS levels and classify the lesions in ESS categories (see supplemental
section for details). From the available coronary arteries, 142 subsegments were analyzed
with real time PCR, immunohistochemical staining, histochemical staining, zymography and
a heparanase activity assay as described in the supplemental methods section.
2.2. Cell Culture and Western Blotting
A human monocyte cell line (THP-1, ATCC) was maintained in RPMI media with 10%
Fetal Bovine Serum and mercaptoethanol. The cells were induced with Phorbol Myristate
Acetate (PMA) for five days to induce differentiation into macrophages. The cells were
treated with 50 μg/ml LDL, 50 μg/ml copper oxidized LDL or 10 μM angiotensin II (Sigma)
overnight. The cells were then washed twice with PBS and harvested in the extraction buffer
containing 20 mM Tris (pH = 7.0), 0.5% Triton X-100 and protease inhibitors. The extracts
were sonicated for 10 minutes. Cell debris was removed by centrifugation at 12,000g for 10
minutes at 4°C.
2.3 Meaurement of Heparanase Activity
The cell or tissue samples were lysed in lysis buffer containing 0.5% triton X-100 and
protease inhibitors and assayed according to the manufacture’s instructions (CisBio,
Bedford, MA). Briefly, 3 μl of lysates in dilution buffer was added into microtubes. After 10
min pre-incubation at 37°C, an enzyme reaction was initiated by adding 6.0 μl of Bio-HS-
Eu(K) (4.2 ng in 0.2 M NaCH3CO2 pH 5.5), and the microtubes were incubated for 30 min
at 37°C. To stop the enzyme reaction and detect the remaining substrate, 12 μl of a 1.0 μg/
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ml SA-XLent solution wase added into the microtubes. After a 15 min incubation at RT, 20
μl of the reaction mixture was transferred to a 384 microplate and read using excitation at
337 nm with readings taken at emissions 620 nm and 665 nm.
3. Results
3.1. Heparanase protein and mRNA levels are enhanced in TCFA lesions
We examined atherosclerotic lesions formed in pigs after 30 weeks post-induction of
diabetes and hyperlipidemia. Atherosclerotic lesions were histopathologically classified into
minimal (MIN), intermediate (INT) and thin cap fibroatheroma (TCFA) lesions. We found
that heparanase staining and gene expression were increased in TCFA lesions when
compared to minimal or intermediate lesions (Figure 1a–c). Immunohistochemical staining
for heparanase revealed a similar pattern of heparanase staining to immunohistochemical
detection of inflammatory cells by CD45 staining (Figure 1a).
3.2. Heparanase staining co-localizes with inflammatory cells, gelatinase zymography and
MMP-2 Immunostaining
Matrix metalloproteases degrade extracellular matrix and are established markers of
atherosclerosis and contributors to the formation of vulnerable plaques[16]. We
hypothesized that heparanase expression was enhanced due to the increased number of
inflammatory cells in severe plaques and, thus, may be expressed in a similar distribution to
inflammatory cells and, consequently matrix metalloproteases. Dual immunostaining of
arteries for heparanase and CD45 demonstrated colocalization between heparanase and
inflammatory cells within atherosclerotic plaques (Figure 2a). We visualized gelatinase
activity within the tissues by treating sections with quenched fluorescein-labeled gelatin
followed by immunohistochemical staining for heparanase. This analysis revealed that in-
situ gelatinase activity was colocalized with heparanase immunostaining in intermediate and
TCFA plaques (Figure 2b). We also co-immunostained for heparanase and MMP-2 and
found these molecules to be colocalized in the inflamed regions of the atheromas (Figure
2c).
3.3. Heparanase protein and gene expression were increased in plaques under low ESS
Endothelial shear stress (ESS) is a crucial factor in the development of TCFA morphology
and an important predictor of vulnerable plaque development[15,17–20]. We performed
vascular profiling at weeks 23 and 30 with intravascular ultrasound and used these results to
calculate local shear stress with a computational model of fluid flow. An example of a
calculate shear stress map for an artery is shown in Figure 3a. For analysis, we categorized
arterial subsegments into those with ESS greater than or equal to 1.0 Pa and those less than
1.0 Pa at week 23. Heparanase expression and staining was 3.5 fold greater in subsegments
with low ESS (Figure 3b–d).
3.4. Association of heparanase and proteoglycan expression with fragmentation of internal
elastic lamina (IEL)
Extracellular matrix protease activity contributes to degradation of the IEL, compromising
IEL integrity and facilitating macrophage and vascular smooth muscle cell migration[21,22].
We examined the heparanase expression in lesions with varying levels of IEL fragmentation
as quantified by Verhoeff’s staining and histomorphometric quantification. This analysis
revealed a significant increase in heparanase in plaques with severe versus minimal IEL
fragmentation (Figure 4a and 4b). The overall magnitude of heparanase mRNA expression
did not show statistically significant differences (data not shown).
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3.5. Low density lipoprotein (LDL), oxidized LDL and angiotensin II increase heparanase
activity in human macrophages
To better understand if the alterations in heparanase expression led to higher levels of
increased arterial heparanase enzymatic activity, we lysed cryosections from arterial
subsegments aand measured heparanase activity relative to total protein content. A two-fold
increase in heparanase activity was found in TCFA lesions in comparison to MIN and INT
lesions (Figure 5a). Similarly, arteries with low ESS had an increase in heparanase activity
(Figure 5b). From our immunostaining analysis it appears that macrophages may be the
primary source of heparanase within the atherosclerotic plaque. We hypothesized that
increased LDL or angiotensin II might responsible for the increased heparanase expression
observed in the arteries. To examine the potential mechanisms of increased heparanase
activity in atherosclerotic plaques we exposed human macrophages in culture to LDL,
oxidized LDL or angiotensin II. Exposure to these factors increased the activity of
heparanase in the cells by 20–50% (Figure 5c).
4. Discussion
One intriguing aspect of fibroatheromatous plaque stabilization has been the emergence of
enzymatic regulation as a dominant force in atherosclerotic arterial remodeling. Early work
on atherosclerosis suggested that there was an upregulation of matrix metalloproteases in
severe atherosclerotic plaques[23,24]. This observation has led to nearly two decades of
scientific inquiry identifying a complex cascade of enzymatic regulation of atheroma
development and maturation[25]. The balance of collagen synthesis and degradation is
critical to determining risk of plaque rupture and is under the relative control of the MMPs
and their endogenous inhibitors[23,24]. A major advancement in the understanding of
atherosclerosis was the advent of the “vulnerable plaque” concept, which asserts that among
the many plaques that form in an individual’s life only a select few go on to develop a
specific morphology and composition that makes them prone to acute rupture and
thrombosis[1,2]. In the continuum of atheroma morphology, vulnerable plaques are thought
to be those with lowered collagen content and a thin, acellular cap over a lipid-rich core
region. Thus, the regulation of the extracellular matrix is a key aspect to stabilizing these
plaques by preventing plaque cap thinning and eventual rupture. Thin cap fibroatheroma
morphology in swine has been found to associate with plaque rupture[26]. Swine with thin
cap lesions also exhibit sudden coronary death when under stress[27]. In addition, similar
morphology in humans has been extensively linked with plaque rupture[28–31]. In this work
we sought to examine the enzymatic regulation of heparan sulfate by heparanase during the
natural history of atherosclerotic plaque development in the coronary arteries of
hyperlipidemic, diabetic swine. Our results demonstrate that heparanase accumulation and
activity is strongly increased in TCFAs and in arteries with risk factors that enhance TCFA
formation including low ESS and fragmented IEL. Together these results suggest a role for
heparanase in atherogenesis and progression of plaque severity.
Heparanase protein levels and activity increased with progression of atherosclerotic lesions
from minimal lesions to TCFAs. A critical comparison is that of the intermediate and TCFA
lesions as this represents the transition from a stable to potentially unstable lesion. A greater
than three-fold increase in heparanase between these two groups suggests that heparanase
may be involved not only in initial lesion formation but in the progression of stable lesions
to vulnerable plaques. Immunohistochemical analysis of heparanase revealed a pattern of
heparanase accumulation that was similar to lipid deposition and inflammatory cell
distribution suggesting that the major source of heparanase was the inflammatory cells.
Immunohistochemical staining for heparanase in human coronary arteries found it to be
increased in arteries with atherosclerosis versus non-diseased arteries[32], consistent with
our findings here. Lipids have been shown to regulate heparanase expression in some cell
Baker et al. Page 5













types[33]. Our in-vitro studies on human macrophages demonstrated that heparanase activity
can be increased by oxidized LDL and angiotensin II. Thus, oxidized lipid or angiotensin-
induced expression of heparanase in macrophages may be a primary mechanism increasing
heparanase in these plaques.
Both collagen and elastin play an integral role in the atherosclerotic plaque development
process. Collagen is thought to be the major structural protein that maintains plaque
stability. Destruction of this extracellular matrix molecule is therefore key to facilitating
plaque thinning and rupture. Similarly, elastin acts as a barrier to migration of macrophages
and vascular smooth muscle cells. Destruction of the elastic lamina is a critical part of
atherosclerotic plaque progression. In this context, heparanase could act as a facilitator of
the MMP and cathepsin-mediated destruction of extracellular matrix molecules. Heparan
sulfate interacts with fibrillin-1 and is required for effective assembly of elastin fibrils[34].
Thus, removal of these chains may destabilize and prevent repair of elastin fibrils. Several
other synergistic activities of heparanase and MMPs are suggested by previous work. We
recently showed an increase in the expression and activity of MMP-2 and MMP-9 in a
porcine model of atherosclerosis[35]. Removal of heparan sulfate from the cell surface has
been shown to increase activation of MMP-2[36]. Heparanase and MMP-9 can also work
synergistically to enhance the differentiation of vascular smooth muscle cells[37]. We used
gelatinase zymography and heparanase immunostaining to demonstrate co-localization
between MMP activity and heparanase localization. Heparanase and MMP-2 were also co-
localized in the lesions in this study. Together, these results support a mechanism in which
heparanase may act in concert with MMP activity to remodel the atherosclerotic lesions.
A major risk factor for local TCFA formation is the presence of low ESS[15,17]. Low ESS
regulates a number of pro-atherogenic molecules in endothelial cells including the
expression of adhesion molecules such as P-selectin and VCAM-1 as well as paracrine
vascular regulators like nitric oxide and HSPGs[17]. During plaque progression, arterial
cells produce increased amounts of extracellular matrix and matrix degrading enzymes.
These processes facilitate atherosclerotic plaque development and progression to unstable
TCFA morphology. Endothelial HSPGs are known inhibitors of vascular smooth muscle cell
proliferation and migration[10]. A recent paper by van den Berg et al demonstrated that the
dimension and composition of the glycocalyx was altered in high risk atherogenic regions of
the mouse carotid artery [38]. Specifically, the thickness and amount of heparan sulfate in
the glycocalyx was reduced in the carotid sinus versus that in the common carotid. In
addition they demonstrated that the thinner, less heparan sulfate-rich portion of the artery
had increased LDL “leakage” into the intimal layers of the artery. These results imply that
loss of the glycocalyx layer, by disturbed flow and/or hyperlipidemia, may lead to enhanced
arterial accumulation of lipids. Our studies are consistent with these results and
demonstrated that heparanase is increased in arterial regions with low ESS. In this context,
heparanase activity would lead to loss of heparan sulfate from the glycocalyx and enhanced
lipid permeability to lipoproteins. Thus, heparanase may have an important role in the well-
known atherogenic effects of low or disturbed flow within the artery through altering the
glycocalyx.
Taken together, our results suggest a role for heparanase as an enzymatic regulator of the
progression and development of atherosclerotic plaques. Our experiments were performed in
an advanced model of atherosclerosis that demonstrates human-like atheroma development
allowing the study of the stable to unstable plaque transition. In this context, heparanase was
associated with proatherogenic risk factors and severe plaque remodeling. Further, co-
localization of heparanase with macrophages and MMP activity suggests that heparanase
may work in concert with proteases to enhance TCFA formation. These results suggest a
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critical role for heparanase as an enzymatic regulator of vulnerable lesion development and
potential target for future therapeutic treatment of atherosclerosis.
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Figure 1. Heparanase staining, mRNA and activity are increased in severe atheromas
Lesions were histopathologically classified as minimal lesions (MIN, n=26), intermediate
lesions (INT, n=56) or thin cap fibroatheromas (TCFAs, n=60) based on morphologic and
oil O red staining. (A) Immunohistochemical staining for heparanase was increased with
progression from MIN to TCFA lesions. Bar = 500 μm. (B) Quantitative analysis of
heparanase staining within arteries. (C) Gene expression analysis by real time PCR revealed
increased expression of heparanase. *Statistically different from MIN group with
p<0.05. **Statistically different from MIN and INT groups with p<0.05.
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Figure 2. Heparanase protein is co-localized with CD45, gelatinase activity and MMP-2
immunostaining
(A) Immunofluorescence staining demonstrates co-localization between heparanase and
CD45 positive cells. (B) Gelatinase zymography and immunostaining for heparanase (HPA)
were performed on tissue sections. Colocalization was found between gelatinase activity and
heparanase immunostaining. Representive samples are shown for intermediate lesions (INT)
or thin cap fibroatheroa (TCFA) lesions. (C) Immunofluorescence staining demonstrated co-
localization between heparanase and MMP-2. Bar = 50 μm. L = Lumen. I = Intima. M =
Media.
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Figure 3. Local heparanase expression is increased in arterial segments with low endothelial
shear stress
Arterial segment morphology was measured using intravascular ultrasound and
computational modeling used to calculate ESS. The segments were separated into groups of
those with ESS less than 1.0 Pa (n=76) or with greater than or equal to 1.0 Pa (n=66) for
analysis. (A) Shear stress maps calculated from intravascular ultrasound. Shown are
histological slides from two regions of the same artery. The box shows the region from
which the histological sections were taken. (B and C) Heparanase protein levels were
increased with low ESS as measured by immunohistochemical staining. Bar = 500 μm. (D)
Gene expression analysis by real time PCR revealed increased expression of heparanase in
arteries with low ESS. *p < 0.05 versus high ESS group.
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Figure 4. Heparanase is increased in arteries with degraded internal elastic laminae (IEL)
Based on histomorphology following elastic fiber staining, arterial subsegments were
categorized into the following groups: group 0, no IEL breaks (n=22); group 1, minimal IEL
breaks (n=22); group 2, numerous IEL breaks (n=56); and group 3, severe IEL and medial
fragmentation (n=42). (A and B) Staining for heparanase is increased in arteries with severe
IEL fragmentation. Bar = 500 μm. *p<0.05 versus IEL grade 0 group. **p < 0.05 versus all
other groups.
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Figure 5. Heparanase enzymatic activity is increased in TCFA lesions, subsegments with low
ESS and in macrophages treated with oxidized LDL and angiotensin
A FRET-based heparanase was used to measure heparanase activity in lysed arterial
sections. (A) Lesions with TCFA morphology have a two-fold increase in heparanase
activity in comparison with intermediate and minimal lesions. *p < 0.05 versus MIN and
INT groups. (B) Subsegments with low ESS have increased heparanase activity. *p < 0.05
versus high ESS group. (C) Human macrophages in culture were treated with LDL (50 μg/
ml) or angiotensin II (10 μg/ml) for 24 hours. The cells were lysed and heparanase activity
was measured. *p < 0.05 versus control group.
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